Get the Stockscreener App
24.71
1.89%
-0.475
After Hours:
24.65
-0.065
-0.26%
Moderna Inc stock is traded at $24.71, with a volume of 6.68M.
It is down -1.89% in the last 24 hours and down -28.80% over the past month.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
See More
Previous Close:
$25.19
Open:
$25.28
24h Volume:
6.68M
Relative Volume:
0.61
Market Cap:
$10.36B
Revenue:
$5.06B
Net Income/Loss:
$-2.22B
P/E Ratio:
-4.2466
EPS:
-5.82
Net Cash Flow:
$-3.96B
1W Performance:
+0.88%
1M Performance:
-28.80%
6M Performance:
-54.92%
1Y Performance:
-76.11%
1-Day Range:
$24.43
$25.28
1-Week Range:
$24.26
$27.21
52-Week Range:
$23.15
$170.47
Moderna Inc Stock (MRNA) Company Profile
Name
Moderna Inc
Sector
Industry
Phone
(617) 714-6500
Address
325 BINNEY STREET, CAMBRIDGE
Compare MRNA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
24.71 | 10.36B | 5.06B | -2.22B | -3.96B | -5.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-13-25 | Initiated | Citigroup | Neutral |
| Feb-18-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Jan-29-25 | Downgrade | Goldman | Buy → Neutral |
| Dec-18-24 | Downgrade | Argus | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-19-24 | Initiated | Berenberg | Hold |
| Nov-18-24 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Sep-13-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Sep-13-24 | Downgrade | Jefferies | Buy → Hold |
| Sep-13-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-28-24 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-07-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Aug-05-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-26-24 | Downgrade | HSBC Securities | Hold → Reduce |
| Jan-02-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-29-23 | Initiated | Canaccord Genuity | Hold |
| Nov-03-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Nov-02-23 | Downgrade | Deutsche Bank | Hold → Sell |
| Aug-04-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Aug-03-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Jul-24-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jun-26-23 | Upgrade | UBS | Neutral → Buy |
| Apr-26-23 | Initiated | Guggenheim | Neutral |
| Mar-13-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Mar-02-23 | Initiated | RBC Capital Mkts | Outperform |
| Feb-24-23 | Downgrade | SVB Securities | Market Perform → Underperform |
| Dec-19-22 | Upgrade | Jefferies | Hold → Buy |
| Dec-14-22 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-21-22 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Sep-08-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-01-22 | Upgrade | Redburn | Sell → Neutral |
| Jan-26-22 | Upgrade | Deutsche Bank | Sell → Hold |
| Jan-21-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-21-22 | Initiated | UBS | Neutral |
| Dec-07-21 | Initiated | Cowen | Market Perform |
| Nov-09-21 | Initiated | Wolfe Research | Outperform |
| Oct-22-21 | Initiated | Deutsche Bank | Sell |
| Oct-15-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-06-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-06-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-15-21 | Reiterated | Jefferies | Hold |
| Feb-01-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-16-20 | Downgrade | Jefferies | Buy → Hold |
| Dec-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-20 | Downgrade | Needham | Buy → Hold |
| Nov-23-20 | Initiated | Wells Fargo | Equal Weight |
| Nov-17-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Sep-08-20 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-23-20 | Initiated | SVB Leerink | Mkt Perform |
| Jul-20-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-13-20 | Initiated | Jefferies | Buy |
| Jun-30-20 | Initiated | Argus | Buy |
| Jun-08-20 | Initiated | Barclays | Overweight |
| Apr-30-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-05-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Dec-03-19 | Resumed | BofA/Merrill | Buy |
| Oct-25-19 | Initiated | ROTH Capital | Buy |
| Apr-05-19 | Initiated | Chardan Capital Markets | Buy |
View All
Moderna Inc Stock (MRNA) Latest News
Where Will Moderna Be in 5 Years? - Nasdaq
Advisory Services Network LLC Purchases 16,555 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Q1 Earnings Forecast for Moderna Issued By Leerink Partnrs - MarketBeat
Lobbying Update: $60,000 of MODERNA INC. lobbying was just disclosed - Nasdaq
Moderna (NASDAQ:MRNA) Earns Market Perform Rating from William Blair - MarketBeat
Altshuler Shaham Ltd Grows Position in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Scotia Capital Inc. Reduces Stake in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Russell Investments Group Ltd. Increases Stock Position in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Bank of Montreal Can Trims Stock Position in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
The Gutierrez Co. Sued Over Mold, Water Damage at Moderna Site — Boston Business Journal - Boston Real Estate Times
Moderna sues construction firm claiming leaks, mold at new drug plant - NBC Boston
Bridgewater Associates LP Invests $25.19 Million in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Water leaks, mold plague Moderna's new manufacturing site, lawsuit claims - The Business Journals
Moderna, Inc. (NASDAQ:MRNA) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
Quinn Opportunity Partners LLC Purchases Shares of 16,500 Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna (MRNA) Stock Drops Despite Market Gains: Important Facts to Note - Yahoo Finance
US Advisory Panel Votes To Expand Recommendation For Pfizer, GSK's RSV Vaccines For Older Adults Below 60 Years - Benzinga
Invesco Ltd. Acquires 979,858 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna Says New Drug Plant Riddled With Defects, Mold - Law360
Moderna, Inc. (NASDAQ:MRNA) Shares Sold by Legal & General Group Plc - MarketBeat
Moderna (MRNA) Leads Healthcare Short Interest in March - GuruFocus
Lansdowne Partners UK LLP Acquires New Holdings in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna, Inc. (NASDAQ:MRNA) Shares Sold by Neuberger Berman Group LLC - MarketBeat
Bloom Energy, Rogers, 3D Systems, Moderna, and EchoStar Stocks Trade Down, What You Need To Know - The Globe and Mail
Moderna permitted to start commercial mRNA vaccine manufacture in UK - The Pharma Letter
Leerink Partners Adjusts Moderna Price Target to $23 From $27, Maintains Underperform Rating - marketscreener.com
Moderna Co-Founder and MIT Legend Strengthens Decoy Therapeutics Drug Development Team - Stock Titan
MRNA Based Vaccines and Therapeutics Therapeutics Market Size - openPR.com
APG Asset Management N.V. Has $9.15 Million Stock Holdings in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Renaissance Technologies LLC Purchases 700,458 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
FDA Special Assistant Høeg’s Vaccine Concerns On Display At ACIP - insights.citeline.com
Moderna, Inc. (NASDAQ:MRNA) Shares Sold by Shelton Capital Management - MarketBeat
Stocks Edge Up On Strong Bank Earnings, Netflix Soars, Dollar Rebounds: What's Driving Markets Tuesday? - Benzinga
Goldman Sachs Adjusts Moderna's Price Target to $35 From $49, Keeps Neutral Rating - MarketScreener
Redburn Atlantic Adjusts Moderna's Price Target to $52 From $55, Keeps Neutral Rating - MarketScreener
Morgan Stanley Issues Pessimistic Forecast for Moderna (NASDAQ:MRNA) Stock Price - MarketBeat
Aviva PLC Lowers Position in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Resona Asset Management Co. Ltd. Buys Shares of 94,753 Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Fmr LLC Has $776.08 Million Stock Holdings in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Sit Investment Associates Inc. Sells 10,675 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna (NASDAQ:MRNA) Sets New 1-Year LowTime to Sell? - MarketBeat
Lobbying Update: $50,000 of MODERNA US INC. lobbying was just disclosed - Nasdaq
RFK Jr Asks If Taxpayer-Funded Healthcare Should Be Accessible To People Smoking 'Three Packs A Day' - Benzinga
11,987 Shares in Moderna, Inc. (NASDAQ:MRNA) Acquired by Aster Capital Management DIFC Ltd - MarketBeat
First Week of May 30th Options Trading For Moderna (MRNA) - Nasdaq
Moderna Inc Stock (MRNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):